Detalhe da pesquisa
1.
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
Blood
; 115(16): 3206-14, 2010 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20154213
2.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Blood
; 111(9): 4477-89, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18285545
3.
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Leukemia
; 32(7): 1657-1669, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29925908
4.
[Treatment of children and adolescents with relapsed ALL: therapy target long-term healing]. / Behandlung von Kindern und Jugendlichen mit Rezidiv einer ALL : Therapieziel langfristige Heilung.
Pharm Unserer Zeit
; 41(3): 214-21, 2012 May.
Artigo
em Alemão
| MEDLINE | ID: mdl-22844668
5.
Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group.
Eur J Cancer
; 47(1): 90-7, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20970323
6.
Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
J Clin Oncol
; 27(20): 3363-9, 2009 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19433688